Top Page
Eli Lilly & Co
(NYSE:LLY)
Eli Lilly & Co (LLY) vs. SPDR S&P 500 ETF (SPY)
Eli Lilly & Co Business Overview & Revenue Model
Eli Lilly & Co Key Performance Indicators (KPIs)
Shows revenue distribution across different business units or product lines, highlighting which areas drive growth and which may need strategic adjustments.
Main Street DataEli Lilly & Co Earnings Call Summary
Eli Lilly & Co Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 59.42B | 45.04B | 34.12B | 28.54B | 28.32B | 24.54B |
| Gross Profit | 49.34B | 36.62B | 27.04B | 21.91B | 21.01B | 19.06B |
| EBITDA | 25.12B | 15.23B | 8.57B | 8.66B | 8.04B | 8.91B |
| Net Income | 18.41B | 10.59B | 5.24B | 6.24B | 5.58B | 6.19B |
Balance Sheet | ||||||
| Total Assets | 114.94B | 78.71B | 64.01B | 49.49B | 48.81B | 46.63B |
| Cash, Cash Equivalents and Short-Term Investments | 9.91B | 3.42B | 2.93B | 2.21B | 3.91B | 3.68B |
| Total Debt | 42.51B | 33.64B | 25.23B | 16.24B | 16.88B | 16.60B |
| Total Liabilities | 91.08B | 64.44B | 53.14B | 38.71B | 39.65B | 40.81B |
| Stockholders Equity | 23.79B | 14.19B | 10.77B | 10.65B | 8.98B | 5.64B |
Cash Flow | ||||||
| Free Cash Flow | 9.02B | 414.30M | -3.15B | 4.60B | 5.39B | 4.47B |
| Operating Cash Flow | 16.06B | 8.82B | 4.24B | 7.59B | 7.37B | 6.50B |
| Investing Cash Flow | -10.09B | -9.30B | -7.15B | -3.76B | -2.87B | -2.26B |
| Financing Cash Flow | 440.40M | 1.23B | 3.50B | -5.41B | -4.13B | -3.14B |
Eli Lilly & Co Technical Analysis
Eli Lilly & Co Risk Analysis
Eli Lilly & Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $214.76B | 11.37 | ― | 3.93% | 1.74% | ― | |
| ― | $448.76B | 17.98 | 33.62% | 2.73% | 5.08% | 71.07% | |
| ― | $251.51B | 30.44 | 19.76% | 1.90% | 15.08% | 29.15% | |
| ― | $847.56B | 44.34 | 96.82% | 0.70% | 45.41% | 120.94% | |
| ― | $234.73B | 16.76 | 32.93% | 3.23% | 11.53% | -15.21% | |
| ― | $374.44B | 159.25 | ― | 3.01% | 7.40% | ― | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Eli Lilly & Co Corporate Events
Eli Lilly and Company is a global pharmaceutical firm known for its innovative research and development in the healthcare sector, focusing on treatments for diabetes, cancer, and other significant health challenges. In its latest earnings report, Eli Lilly announced a robust 54% increase in revenue for the third quarter of 2025, reaching $17.60 billion, primarily driven by the strong performance of its key products, Mounjaro and Zepbound. The company’s earnings per share (EPS) also saw a significant rise, with reported EPS increasing to $6.21 and non-GAAP EPS reaching $7.02.
Eli Lilly and Company is spearheading a pivotal Phase 3 clinical study titled ‘A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE).’ The primary aim of this study is to assess the efficacy of baricitinib in preserving beta-cell function in individuals newly diagnosed with type 1 diabetes, a critical aspect of managing this chronic condition.
Study Overview: Eli Lilly and Company is conducting a Phase 3 clinical trial titled A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Delay Stage 3 Type 1 Diabetes in At-risk Participants Aged ≥1 to <36 Years. The study aims to determine if baricitinib can delay the onset of clinical type 1 diabetes in individuals at high risk of developing the condition, with participation lasting up to five years.
Study Overview: Eli Lilly and Company is conducting a study titled ‘Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-20020 With BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.’ The study aims to evaluate the long-term safety of pirtobrutinib in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously been treated. This research is significant as it offers continued access to treatment for participants and seeks to ensure the safety of long-term use.
Study Overview: Eli Lilly and Company is conducting a Phase 3 clinical trial titled ‘FORAGER-2’ to evaluate the efficacy and safety of Vepugratinib combined with Enfortumab Vedotin and Pembrolizumab in adults with untreated locally advanced or metastatic urothelial carcinoma with an FGFR3 genetic alteration. This study aims to determine if Vepugratinib, in combination with standard care therapies, can provide a significant treatment advantage for patients with advanced bladder cancer.
Study Overview: Eli Lilly and Company is spearheading a Phase 2 clinical study titled ‘A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis.’ The study aims to assess the effectiveness and safety of LY4268989 when used alongside mirikizumab, compared to mirikizumab alone, in treating adults with moderately to severely active ulcerative colitis (UC).
Study Overview: Eli Lilly and Company is conducting a Phase 1 study titled A Phase 1, 2-Part Study to Determine the Effect of Injection Site on the Relative Bioavailability of a Single Subcutaneous Dose of LY3537031 and to Evaluate the Pharmacokinetics of a Single Intravenous Dose of LY3537031 in Healthy Participants. The study aims to assess how LY3537031 is absorbed into the bloodstream and eliminated from the body when administered subcutaneously or intravenously, focusing on safety and tolerability in healthy individuals.
Eli Lilly and Company recently completed a clinical study titled ‘A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors.’ The study aimed to evaluate the safety and effectiveness of abemaciclib, a cancer drug, when used with other treatments in young patients with solid tumors that did not respond to previous therapies. This research is significant as it explores potential new treatment combinations for challenging cancer cases.
Study Overview: Eli Lilly and Company recently completed a Phase 3 study titled ‘A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2)’. The study aimed to evaluate the safety and effectiveness of orforglipron, an oral medication, in improving blood sugar control in adults with type 2 diabetes who have inadequate glycemic control with metformin.
Eli Lilly and Company recently updated its clinical study titled A Phase 2b Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes. The study aims to assess the effectiveness and safety of bimagrumab and tirzepatide, either alone or combined, in reducing body weight among adults with obesity or overweight who have type 2 diabetes.
Eli Lilly and Company recently completed a clinical study titled ‘A Randomized, Double-Blind, Phase 1 Study to Investigate the Effect of LY3437943 Versus Placebo on Calorie Intake and Energy Expenditure in Participants With Obesity Under Calorie Restriction.’ The study aimed to assess the impact of LY3437943, a new drug, on calorie consumption, energy metabolism, and appetite in individuals with obesity, highlighting its potential significance in obesity treatment.
Eli Lilly and Company recently completed a Phase 3 study titled A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor. The study aimed to evaluate the safety and efficacy of orforglipron, a new oral medication for adults with Type 2 Diabetes who have not achieved adequate glycemic control with their current insulin regimen.
Study Overview: Eli Lilly and Company conducted a Phase 1 study titled A Phase 1 Study of LY3127804 as Monotherapy and in Combination With Ramucirumab in Patients With Advanced Solid Tumors. The study aimed to evaluate the safety of LY3127804, both alone and combined with Ramucirumab, in patients with advanced or metastatic solid tumors. This research is significant as it explores potential new treatments for challenging cancer conditions.
Study Overview: Eli Lilly and Company is conducting a Phase 3 study titled ‘A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1)’. The study aims to evaluate the effectiveness and safety of brenipatide in treating adults with moderate-to-severe Alcohol Use Disorder (AUD), a significant public health concern.
Study Overview: Eli Lilly and Company is spearheading a Phase 3 clinical study titled A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Alcohol Use Disorder (RENEW-ALC-2). The study aims to evaluate the effectiveness and safety of brenipatide in treating adults with Alcohol Use Disorder (AUD) and hazardous alcohol use, a condition with significant health implications.
Study Overview: Eli Lilly and Company is initiating a Phase 2 clinical study titled A Phase 2, Multicenter, Randomized, Double-blind, 52-week Study, to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Uncontrolled Moderate to Severe Asthma. The study aims to evaluate the safety and efficacy of brenipatide, a potential new treatment for asthma, which could significantly impact the management of this chronic condition.
Study Overview: Eli Lilly and Company, in collaboration with Cipla Ltd., recently completed a Phase 4 clinical study titled A 26-Week, Multicenter, Open-Label, Single-Arm, Phase 4 Study to Assess The Safety of Lyumjev in Adult Patients With Type 2 Diabetes Mellitus in India. The study aimed to evaluate the safety of insulin lispro-aabc in adults with Type 2 diabetes mellitus, a significant step in enhancing diabetes management in India.
Study Overview: Eli Lilly and Company recently completed a clinical study titled A Multiple Dose Combination Study to Evaluate the Safety and Tolerability of Tirzepatide and LY3841136 in Overweight and Obese Participants. The study aimed to assess the safety and tolerability of the drug combination in overweight and obese patients, highlighting its significance in addressing obesity-related health issues.
Study Overview: Eli Lilly and Company is conducting a Phase 2 study titled A Phase 2, Randomized, Open-Label, Comparator-Controlled Trial to Evaluate the Efficacy and Safety of LY3938577 in Study Participants, With Type 2 Diabetes Previously Treated With Basal Insulin. The study aims to assess the efficacy and safety of LY3938577 compared to degludec in individuals with type 2 diabetes, highlighting its potential significance in diabetes treatment advancements.
Eli Lilly and Company is conducting a Phase 2 clinical study titled A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes. The study aims to explore the effectiveness of the drugs Macupatide and Eloralintide, either individually or combined, in reducing weight among adults with obesity or overweight who also have Type 2 diabetes.
Eli Lilly and Company is spearheading a groundbreaking study titled A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes. The study aims to evaluate the effectiveness of retatrutide and tirzepatide in preventing major adverse liver outcomes in adults with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD).
Study Overview: Eli Lilly and Company is initiating a Phase 3 clinical study titled A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight. The study aims to evaluate the effectiveness and safety of Orforglipron in treating stress urinary incontinence (SUI) in overweight or obese women, a condition characterized by involuntary urine leakage during physical activities.
Study Overview: Eli Lilly and Company is conducting a study titled ‘A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)’. The study aims to assess the safety, side effects, and efficacy of LY4337713 in participants with advanced or metastatic cancers that express high levels of fibroblast activation protein (FAP). This research is crucial for developing targeted cancer therapies.
Eli Lilly and Company is conducting a two-part Phase 3 study titled ‘FRAmework-01’ to evaluate the efficacy and safety of LY4170156 in patients with ovarian, peritoneal, and fallopian tube cancers. The study aims to determine if LY4170156 is more effective than existing treatments for patients whose cancers are either resistant or sensitive to platinum-based therapies.
Eli Lilly and Company recently completed a Phase 1 study titled A Phase 1, Relative Bioavailability Study of Bimagrumab (LY3985863) Test and Reference Materials, and Bimagrumab Test Material Coadministration and Coformulation With Tirzepatide (LY900042), in Healthy Participants. The study aimed to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide, over approximately 4.5 months.
Eli Lilly and Company is conducting a first-in-human study titled First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors. The study aims to evaluate the safety, tolerability, and preliminary antitumor activity of STX-478 in patients with advanced solid tumors, particularly those with PI3Kα mutations. This research is significant as it explores new treatment avenues for challenging cancer types.
Study Overview: Eli Lilly and Company initiated a study titled A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease. The study aimed to evaluate the efficacy and safety of Volenrelaxin in treating adults with Chronic Kidney Disease over a 24-week period.
Study Overview: Eli Lilly and Company is conducting a Phase 1 study titled A Phase 1, Multicenter, Parallel-Design, Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment. The study aims to understand how LY3537031 is processed in the body of individuals with varying levels of kidney function, including those with renal impairment and end-stage renal disease (ESRD).
Study Overview: Eli Lilly and Company is conducting a Phase 1 study titled A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment. The primary goal is to understand how LY3537031 is processed in the body across different levels of liver function, focusing on its absorption, distribution, and elimination, as well as its safety and tolerability.
Eli Lilly and Company recently completed a Phase 1 clinical study titled A Randomised Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3876602 in Healthy Participants. The study aimed to assess the safety, tolerability, and pharmacokinetics of LY3876602, a new drug administered in single and multiple ascending doses to healthy participants. This study is significant as it lays the groundwork for understanding the drug’s behavior in the human body, which is crucial for future development stages.
Study Overview: Eli Lilly and Company recently completed a Phase 3 study titled A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-3). The study aimed to evaluate the efficacy and safety of orforglipron compared to semaglutide in adults with Type 2 diabetes inadequately controlled with metformin, highlighting its significance in advancing diabetes treatment options.
Study Overview: Eli Lilly and Company recently completed a study titled An Open-Label, Nonrandomized, Single-Dose, Safety and Pharmacokinetic Study of LY3537982 in Participants With Hepatic Impairment and Healthy Participants. The primary aim was to evaluate how the drug olomorasib enters the bloodstream and is processed by the body in individuals with varying degrees of liver impairment compared to those with normal liver function. The study also assessed the safety and tolerability of olomorasib.
Study Overview: Eli Lilly and Company recently completed a Phase 3 study titled A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2). The study aimed to assess the safety and effectiveness of orforglipron, a once-daily oral treatment, in reducing body weight among adults with obesity or overweight and type 2 diabetes.
Eli Lilly and Company, in collaboration with Pfizer, is conducting a Phase 3 clinical study titled A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2). The study aims to evaluate the efficacy and safety of LY4064809 in combination with other anti-cancer treatments for advanced breast cancer patients with specific genetic mutations.
Eli Lilly and Company is conducting a Phase 2 study titled ‘A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease.’ The study aims to assess the effectiveness and safety of LY3537021 in managing nausea and vomiting caused by chemotherapy, a significant concern for cancer patients.
Study Overview: Eli Lilly and Company recently completed a Phase 1 clinical trial titled ‘A First-In-Human Study of LY3985297 in Healthy Participants.’ The study aimed to assess the safety, tolerability, and pharmacokinetics of LY3985297 when administered as single or multiple doses in healthy individuals. This research is significant as it lays the groundwork for understanding the drug’s potential future applications.
Study Overview: Eli Lilly and Company is conducting a study titled ‘Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers.’ The study aims to evaluate the long-term safety of pirtobrutinib in individuals with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma who have previously been treated. This research is significant as it seeks to provide insights into the sustained safety profile of pirtobrutinib, potentially impacting treatment protocols for these blood cancers.
Eli Lilly and Company recently completed a Phase 1 clinical study titled ‘A Phase 1, Open-label, 2-part Study of the Absorption, Metabolism, Excretion, and Bioavailability of [14C]-LY4065967 in Healthy Male Participants.’ The study aimed to understand how the body absorbs, metabolizes, and excretes LY4065967, providing insights into its bioavailability. This research is significant as it helps determine the drug’s potential effectiveness and safety profile.
Eli Lilly and Company is conducting a study titled A Multiple-Ascending Dose Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of LY3537031 in Overweight and Obese Participants and Healthy Volunteers. The study aims to assess the safety and effects of the drug LY3537031 in both overweight/obese individuals and healthy participants, highlighting its potential significance in weight management and health.
Eli Lilly and Company is conducting a Phase 1 study titled ‘A Phase 1 Study to Further Investigate the Pharmacokinetics, Safety and Tolerability, Food Effect and Drug-Drug Interaction of LY4268989 (MORF-057) in Healthy Participants.’ The study aims to assess how the body absorbs and processes LY4268989, its safety, and tolerability in healthy individuals, including Japanese and Chinese participants.
Study Overview: The clinical trial titled A Trial of AAVAnc80-hOTOF Gene Therapy in Individuals With Sensorineural Hearing Loss Due to Otoferlin Gene Mutations aims to evaluate the safety and tolerability of a gene therapy for individuals with sensorineural hearing loss caused by otoferlin gene mutations. This study is significant as it explores a potential treatment for a genetic form of hearing loss, which could lead to new therapeutic options for affected individuals.
Study Overview: Eli Lilly and Company is conducting a study titled ‘A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4006896 in Healthy Participants and Participants With Parkinson’s Disease.’ The study aims to assess the safety and effectiveness of LY4006896, a potential treatment for Parkinson’s disease, highlighting its significance in advancing therapeutic options for this condition.
Study Overview: Eli Lilly and Company is conducting a study titled ‘A Single- and Multiple-Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of LY3867070 in Healthy Participants.’ The primary objective is to assess the safety and side effects of the oral drug LY3867070 in healthy individuals, providing insights into how the body processes and responds to the drug.
Eli Lilly and Company is conducting a Phase 1a/1b study titled ‘A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors’. The study aims to evaluate the safety and tolerability of LY4066434, a drug targeting KRAS mutations in advanced or metastatic solid tumors. This research is significant as it addresses difficult-to-treat cancers, potentially offering new therapeutic options.
Study Overview: Eli Lilly and Company is conducting a Phase 3 study titled A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Efficacy and Safety Study of Lebrikizumab/ LY3650150 in Adults With Chronic Rhinosinusitis With Nasal Polyps on a Background Therapy With Intranasal Corticosteroids. The study aims to evaluate the efficacy and safety of lebrikizumab in treating adults with chronic rhinosinusitis and nasal polyps, a condition that significantly impacts quality of life.
Study Overview: Eli Lilly and Company is conducting a Phase 1 study titled A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes. The study aims to evaluate the safety and tolerability of LY4057996, a potential treatment for diabetes, and to understand its pharmacokinetics and pharmacodynamics. This research is significant as it could lead to new treatment options for diabetes, a condition affecting millions worldwide.
Study Overview: Eli Lilly and Company is conducting a clinical study titled A Prospective Diagnostic Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint in Primary and Secondary/Tertiary Care. The study aims to assess the difference in patient management actions between groups undergoing P-tau217 testing and those receiving standard care, highlighting its significance in early cognitive impairment evaluation.
Study Overview: Eli Lilly and Company is conducting a study titled ‘A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3954068 in Patients With Early Symptomatic Alzheimer’s Disease.’ The study aims to assess the safety and effects of LY3954068 in individuals with early Alzheimer’s, focusing on its presence in the bloodstream and impact on disease markers.
Study Overview: Eli Lilly and Company is conducting a study titled ‘Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-18001 With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma.’ The study aims to evaluate the long-term safety and efficacy of pirtobrutinib, providing insights into its potential benefits for patients with these conditions.
Study Overview: Eli Lilly and Company is spearheading a study titled A Longitudinal, Prospective Epidemiology Study in Alzheimer’s Disease: Assessing Neurocognitive and Biomarker Changes and Health Outcomes in Individuals at Risk for Symptoms of Alzheimer’s Disease (ANCHOR-AD). The study aims to evaluate the rates of cognitive decline in individuals with varying levels of plasma P-tau217, a biomarker associated with Alzheimer’s disease. This research is significant as it seeks to enhance understanding of Alzheimer’s progression and potentially guide future therapeutic strategies.
In a significant stride towards advancing cancer treatment, Eli Lilly and Company is currently recruiting participants for a study titled ‘A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib.’ The primary goal of this study is to assess the long-term safety and efficacy of pirtobrutinib, a promising drug for treating Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma. This master protocol will integrate data from various completed studies, allowing participants to continue treatment or follow-up visits, thus providing a comprehensive safety profile.
Study Overview: Eli Lilly and Company is conducting a study titled Pharmacokinetics of LY3537982 Following a Single Dose in Participants With Renal Impairment Compared With Participants With Normal Renal Function. The study aims to determine the appropriate dosage of LY3537982 for individuals with varying degrees of kidney problems, focusing on those with severe renal impairment. This research is significant as it seeks to optimize treatment for patients with renal insufficiency.
Eli Lilly and Company is conducting a Phase 1a/1b clinical study titled A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors. The study aims to evaluate the safety, tolerability, and effectiveness of LY4052031 in patients with advanced or metastatic solid tumors, including urothelial cancer.
Study Overview: Eli Lilly and Company, in collaboration with Prevail Therapeutics, is conducting a Phase 1/2a clinical trial titled ‘A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson’s Disease With at Least One GBA1 Mutation (PROPEL)’. The study aims to assess the safety and effects of LY3884961 in patients suffering from moderate to severe Parkinson’s disease with a GBA1 mutation, highlighting its potential significance in addressing this challenging condition.
Study Overview: Eli Lilly and Company is conducting a Phase 3 study titled ‘Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a).’ The study aims to evaluate the effectiveness of muvalaplin in reducing cardiovascular risk among individuals with high lipoprotein(a) levels who have experienced or are at risk of atherosclerotic cardiovascular events. This research is significant as it targets a specific population with elevated cardiovascular risk, potentially leading to new treatment options.
Eli Lilly and Company is conducting a Phase 3 clinical study titled A Phase 3 Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee. The study aims to evaluate the effectiveness and safety of the drug Orforglipron in individuals with obesity or overweight who also suffer from knee osteoarthritis. This research is significant as it targets a common and painful condition, potentially offering a new treatment option.
Eli Lilly and Company is conducting a Phase 1 clinical study titled ‘A Study of LY4064912 in Healthy Participants and With Overweight or Obesity.’ The study aims to evaluate the safety, tolerability, and pharmacokinetics of LY4064912, a drug administered either subcutaneously or intravenously, in healthy individuals and those with overweight or obesity. This research is significant as it explores potential treatments for obesity-related conditions.
Study Overview: Eli Lilly and Company is conducting a Phase 2 clinical study titled A Phase 2, Double-Blind, Proof of Concept Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder. The study aims to assess the effectiveness of mazdutide in treating individuals with Alcohol Use Disorder (AUD), a significant public health concern.
Eli Lilly and Company, in collaboration with Tango Therapeutics, is conducting a Phase 1/2 clinical study titled Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss. The study aims to evaluate the safety, tolerability, and preliminary antitumor activity of TNG456, a selective PRMT5 inhibitor, both as a monotherapy and in combination with abemaciclib in patients with advanced solid tumors exhibiting MTAP loss. This research is significant as it explores new treatment avenues for challenging cancer types.
Study Overview: Eli Lilly and Company is conducting an open-label, Phase 1 study titled ‘An Open-Label, Phase 1 Study to Investigate the Comparability of the Pharmacokinetics of Olomorasib (LY3537982) Between Two Capsule Formulations and to Evaluate the Food Effect in Healthy Japanese Participants.’ The study aims to compare how food affects the absorption of Olomorasib in the bloodstream when taken in two different capsule forms, highlighting its significance in optimizing dosage forms for better patient outcomes.
Study Overview: Eli Lilly and Company is conducting a clinical study titled A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes. The study aims to evaluate the effectiveness and safety of Orforglipron, a potential treatment for obesity and overweight conditions, with and without type 2 diabetes. This research is significant as it addresses a growing health concern and could lead to new treatment options.
Study Overview: Eli Lilly and Company is conducting a study titled A Single-Dose and Multiple-Ascending Dose Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes. The study aims to evaluate the safety and tolerability of LY4086940, as well as how the drug is processed in the body. This research is significant as it targets conditions like obesity and type 2 diabetes, which are prevalent health concerns.
Study Overview: Eli Lilly and Company is conducting a study titled A Randomized, Double-Blinded Study to Evaluate the Efficacy and Safety of Mevidalen in Patients With Alzheimer’s Disease. The study aims to assess the safety and effectiveness of the drug Mevidalen in alleviating symptoms in individuals with mild to moderate Alzheimer’s Disease dementia. The significance of this study lies in its potential to improve cognitive function, daily activities, and overall quality of life for patients.
Eli Lilly and Company is conducting a Phase 3b study titled A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Retatrutide Treatment in the Maintenance of Weight Reduction in Individuals With Obesity. The study aims to assess the effectiveness of retatrutide in maintaining weight loss among individuals with obesity, highlighting its significance in addressing a prevalent health issue.
Eli Lilly and Company is conducting a study titled ‘A Single-ascending and Multiple-ascending Dose Study of LY3971297 in Healthy Participants and Participants With Obesity and Hypertension and Participants With Decreased Estimated Glomerular Filtration Rate.’ The study aims to evaluate the side effects and pharmacokinetics of LY3971297 when administered subcutaneously in healthy individuals and those with obesity and high blood pressure. This research is significant as it could lead to new treatments for these conditions.
Study Overview: Eli Lilly and Company is conducting a clinical study titled A Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors. The study aims to evaluate the safety, tolerability, and antitumor activity of LY3962673, both as a standalone treatment and in combination with other chemotherapy agents, in patients with advanced solid tumors carrying the KRAS G12D mutation. This research is significant as it targets a specific genetic mutation found in several aggressive cancers, including pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal cancer.
Study Overview: Eli Lilly and Company is conducting a Phase 3 study titled ‘EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence.’ The study aims to evaluate the effectiveness of imlunestrant compared to standard hormone therapy in reducing recurrence risk in patients with early-stage breast cancer.
Study Overview: Eli Lilly and Company is conducting a Phase 1 clinical study titled ‘A Phase 1, Multicenter, Sequential-Design, Single-Dose, Open-Label Study of Lepodisiran in Participants With Normal Hepatic Function and Participants With Mild, Moderate, or Severe Hepatic Impairment.’ The study aims to understand how Lepodisiran is absorbed and metabolized in individuals with varying liver functions, and to evaluate its safety and potential side effects.
Study Overview: Eli Lilly And Company is conducting a Phase 3 clinical trial titled ‘The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)’. The study aims to assess whether retatrutide can reduce major cardiovascular and kidney events in adults with a BMI of 27 kg/m² or higher, who have atherosclerotic cardiovascular disease and/or chronic kidney disease. This research is significant as it targets serious health complications associated with obesity.
Eli Lilly and Company is conducting a Phase 2 clinical study titled A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With LY3841136 and Tirzepatide, Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes. The study aims to evaluate the safety and efficacy of LY3841136, alone or combined with Tirzepatide, for chronic weight management in individuals with Type 2 Diabetes.
Eli Lilly and Company is currently conducting a clinical study titled [Ac-225]-PSMA-62 Phase I/II Clinical Trial to Characterize Efficacy, Safety, Tolerability, and Dosimetry in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (ACCEL). This study aims to evaluate the effectiveness and safety of the drug [Ac-225]-PSMA-62 in treating prostate-specific membrane antigen (PSMA)-positive prostate cancer, a significant step in addressing both hormone-sensitive and castration-resistant forms of the disease.
Study Overview: Eli Lilly and Company is conducting a study titled A Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, PK and PD of LY4006895 in Healthy Volunteers and Patients With Early Symptomatic AD. The study aims to assess the safety and tolerability of LY4006895, a potential treatment for early symptomatic Alzheimer’s Disease (AD), highlighting its significance in addressing a critical health issue.
Eli Lilly and Company is conducting a Phase 2 study titled ‘A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy.’ The study aims to assess the benefits of adding abemaciclib to the standard chemotherapy drug temozolomide for treating high-grade glioma in young patients post-radiotherapy.
Eli Lilly and Company is conducting a Phase 3 clinical study titled ‘A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1).’ The study aims to evaluate the efficacy and safety of lebrikizumab, a potential treatment for perennial allergic rhinitis, a condition characterized by year-round nasal allergies. This study holds significant importance as it could provide a new therapeutic option for individuals suffering from this chronic condition.
Study Overview: Eli Lilly and Company is conducting a Phase 3 clinical study titled ‘A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Dulaglutide 3.0 mg and 4.5 mg in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus.’ The study aims to assess additional dosing options for dulaglutide in children and adolescents with Type 2 Diabetes, highlighting its potential significance in expanding treatment options for this demographic.
Eli Lilly and Company, in collaboration with Loxo Oncology, Inc., is conducting a Phase 2 study titled A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. The study aims to assess the efficacy and safety of three doses of Pirtobrutinib in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously been treated with a covalent Bruton tyrosine kinase inhibitor.
Study Overview: Eli Lilly and Company is conducting a Phase-2 clinical trial titled ‘A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Interventions for Chronic Weight Management in Adult Participants With Obesity or Overweight.’ The study aims to evaluate the safety and efficacy of various investigational interventions for chronic weight management, providing a framework for multiple intervention-specific appendices (ISAs).
Study Overview: Eli Lilly and Company is conducting a clinical study titled ‘A Study of Remternetug Versus Placebo in Early Alzheimer’s Disease Participants at Risk for Cognitive and Functional Decline.’ The study aims to assess the time difference in the development or worsening of memory, thinking, or functional issues in Alzheimer’s patients receiving the drug Remternetug compared to a placebo. This research is significant as it targets early intervention in Alzheimer’s, potentially altering the disease’s progression.
Study Overview: Eli Lilly and Company is conducting a Phase 1 trial titled A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors. The study aims to evaluate the safety, tolerability, and efficacy of LY4101174 in patients with various advanced solid tumors, marking a significant step in cancer treatment research.
Study Overview: Eli Lilly and Company is conducting a study titled ‘Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for the Treatment of Obesity and Weight-Related Comorbidities in Adolescents’ (SURMOUNT-ADOLESCENTS-2). The study aims to evaluate the impact of tirzepatide on body weight and cardiovascular risk factors in adolescents with obesity, alongside healthy nutrition and physical activity. This research is significant as it targets a growing health concern among adolescents.
Eli Lilly and Company is conducting a pivotal study titled A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) – ACCLAIM-Lp(a). The study aims to assess the efficacy of lepodisiran in reducing cardiovascular risks in adults with high lipoprotein(a) levels, either with existing cardiovascular disease or at risk of a first cardiovascular event.
Eli Lilly and Company is conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain.’ The study aims to evaluate the effectiveness and safety of Retatrutide in alleviating chronic low back pain in individuals with obesity or overweight.
Study Overview: Eli Lilly and Company is conducting a Phase 3b clinical trial titled A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight. The study aims to evaluate the efficacy and safety of mirikizumab and placebo compared to mirikizumab with tirzepatide in adults with active Crohn’s Disease and obesity or overweight.
Study Overview: Eli Lilly and Company is conducting a clinical study titled ‘A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)’. The study aims to evaluate the efficacy and safety of orforglipron, a new treatment for hypertension in individuals who are obese or overweight. This research is significant as it could offer a new therapeutic option for managing hypertension, a common condition with serious health implications.
Study Overview: Eli Lilly and Company is conducting a study titled A Phase 1, Participant- and Investigator-Blind, Placebo-Controlled, Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Daily Doses of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus. The study aims to assess the safety and effects of LY3549492 in Chinese individuals with type 2 diabetes, lasting approximately 18 weeks.
Study Overview: Eli Lilly and Company is conducting a Phase 3 study titled A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight. The study aims to evaluate the long-term efficacy and safety of tirzepatide compared to a placebo in adults with type 1 diabetes who are also obese or overweight. This research is significant as it explores a potential new treatment option for managing these conditions.
Study Overview: Eli Lilly and Company is conducting a Phase 3 clinical trial titled ‘A Master Protocol for a Randomized, Controlled, Clinical Platform Trial to Investigate the Efficacy and Safety of Interventions for Chronic Weight Management in Pediatric Participants With Obesity or Overweight.’ The study aims to evaluate the safety and efficacy of pharmacologic agents for managing obesity or overweight in children, addressing a significant public health issue.
Study Overview: Eli Lilly and Company is conducting a study titled A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes. The study aims to evaluate how orforglipron, a new oral medication, aids in weight reduction among individuals with obesity or overweight who also have at least one weight-related health condition, excluding type 2 diabetes. This research is significant as it targets a growing health concern with potential wide-reaching benefits.
Study Overview: Eli Lilly and Company is conducting a study titled A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis. The study aims to assess the efficacy and safety of lebrikizumab compared to a placebo in treating skin lesions associated with this condition, which is significant for improving patient quality of life.
Study Overview: Eli Lilly and Company is conducting a Phase 4 study titled ‘A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)’. The study aims to evaluate the effectiveness of adding tirzepatide to ixekizumab therapy in adults with moderate-to-severe psoriatic arthritis and obesity or overweight, addressing a significant need in clinical practice.
Eli Lilly and Company is conducting a clinical study titled ‘A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study Evaluating LY3848575 in Chronic Neuropathic Pain Associated With Distal Sensory Polyneuropathy.’ The study aims to assess the safety and effectiveness of LY3848575 compared to a placebo in treating nerve pain that starts in the feet and progresses up the leg.
Eli Lilly and Company is conducting a clinical study titled A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants. The study aims to assess the safety and side effects of LY4066708, as well as its absorption and elimination in the body. This research is significant as it could pave the way for new treatments in the field of cancer and other conditions.
Study Overview: Eli Lilly and Company is conducting a clinical study titled A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION). The key objective is to evaluate the efficacy and safety of orforglipron in treating hypertension among individuals with obesity or overweight, highlighting its potential significance in addressing these prevalent health issues.
Eli Lilly and Company is conducting a study titled A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION). The study aims to evaluate the safety and efficacy of orforglipron, a drug intended to treat hypertension in individuals who are obese or overweight.
Eli Lilly and Company is conducting a study titled ‘A Phase 2a, Single-Arm Study to Investigate the Efficacy and Safety of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis.’ The study aims to evaluate the effects of LY3541860 in adults who have not responded adequately to at least one biologic or targeted synthetic disease-modifying antirheumatic drug, highlighting its potential significance in treating this challenging condition.
Study Overview: Eli Lilly and Company is conducting a study titled ‘Efficacy, Safety, and Pharmacokinetics of Orforglipron Once Daily Oral Versus Placebo in Adolescent Participants Who Have Obesity, or Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind Trial (ADVANCE-ATTAIN-ADOLESCENTS)’. The study aims to assess the efficacy, safety, and pharmacokinetics of Orforglipron, a new oral medication, in treating adolescents with obesity or overweight conditions.
Eli Lilly and Company is conducting a study titled ‘A Randomized, Investigator- and Participant-blinded, Multiple-ascending Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus and Healthy Japanese Participants.’ The study aims to assess the safety and side effects of LY3549492, a drug administered orally to both diabetic and healthy participants, by measuring its presence and elimination in the bloodstream.
Study Overview: Eli Lilly and Company is conducting a Phase 3b clinical trial titled A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight. The study aims to evaluate whether the combination of mirikizumab and tirzepatide can reduce symptoms of ulcerative colitis (UC) and achieve significant weight loss in affected individuals.
Study Overview: Eli Lilly and Company is conducting a Phase 3 study titled A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight. The study aims to evaluate the efficacy and safety of tirzepatide, a once-weekly treatment, in adults with type 1 diabetes who are also obese or overweight. This research is significant as it seeks to address the dual challenges of diabetes management and weight control in this patient population.
Study Overview: Eli Lilly and Company is conducting a Phase 2 study titled A Parallel-Group Treatment, Phase 2, Double-Blind Study of Once-Weekly Subcutaneous LY3457263 Compared to Placebo in Participants With Type 2 Diabetes Mellitus on a Stable Dose of Semaglutide or Tirzepatide Who Failed to Achieve HbA1c Goal. The study aims to evaluate the effectiveness of LY3457263 in reducing hemoglobin A1c (HbA1c) levels in type 2 diabetes patients who have not reached their HbA1c targets with semaglutide or tirzepatide.
Study Overview: Eli Lilly and Company is conducting a Phase 4 study titled A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight in Clinical Practice. The study aims to evaluate the effectiveness of adding tirzepatide to ixekizumab therapy in participants with moderate-to-severe plaque psoriasis and obesity or overweight, addressing a significant health concern.
Study Overview: Eli Lilly and Company is conducting a Phase 1 study titled ‘A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4060874 in Healthy Participants.’ The primary objective is to assess the safety and tolerability of the drug LY4060874 in healthy individuals, which is crucial for its future development and potential therapeutic applications.
Eli Lilly and Company is currently conducting a study titled ‘A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes.’ The study aims to evaluate how orforglipron, a new oral medication, can improve glycemic control in individuals with obesity or overweight and type 2 diabetes.
Study Overview: Eli Lilly and Company is conducting a Phase 4 study titled A Phase 4, Multicenter, Open-label, Single-arm Study to Investigate the Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate Atopic Dermatitis and High Itch Burden. The study aims to evaluate the effectiveness of lebrikizumab in reducing eczema symptoms, particularly focusing on areas with high itch burden. This research is significant as it addresses a common and often debilitating symptom of atopic dermatitis.
In a significant advancement for cancer treatment, AstraZeneca and Eli Lilly are collaborating on a Phase 3 clinical study titled ‘SUNRAY-02’. This study aims to evaluate the efficacy and safety of olomorasib in combination with standard immunotherapy for patients with resected or unresectable KRAS G12C-mutant non-small cell lung cancer (NSCLC). The study’s primary objective is to determine if olomorasib, when combined with pembrolizumab or durvalumab, is more effective than the current standard of care treatments.
Eli Lilly and Company is conducting a Phase 3 clinical study titled A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata. The study aims to assess the effectiveness and safety of baricitinib in treating severe alopecia areata in children, a condition characterized by significant hair loss.
Study Overview: Eli Lilly and Company is conducting a Phase 3 clinical trial titled ‘A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)’. The study aims to assess the long-term effectiveness and safety of mirikizumab for treating ulcerative colitis, a chronic inflammatory bowel disease. This research is significant as it could offer a new long-term treatment option for patients with this challenging condition.
Eli Lilly and Company is currently conducting a study titled ‘An Open-Label, Nonrandomized, Single-Dose, Safety and Pharmacokinetic Study of LY3537982 in Participants With Hepatic Impairment and Healthy Participants.’ The study aims to evaluate how the drug olomorasib is absorbed and eliminated in the body among individuals with varying degrees of liver function, alongside assessing its safety and tolerability.
In a recent update, Eli Lilly and Company announced the continuation of their pivotal study titled ‘SUNRAY-01’. This study aims to evaluate the effectiveness of adding LY3537982 (olomorasib) to standard cancer treatments in patients with advanced non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation. The study’s significance lies in its potential to improve treatment outcomes for this specific genetic mutation, which is notoriously challenging to treat.
Study Overview: Eli Lilly and Company is conducting a study titled ‘Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1.’ The purpose is to evaluate the safety and effectiveness of lasmiditan in children aged 6 to 17 suffering from migraines. This study is significant as it aims to provide a new treatment option for pediatric migraine relief.
Study Overview: Eli Lilly and Company is conducting a study titled An Open-label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies With SMARCA4/BRG1 Alterations. The study aims to evaluate the safety, tolerability, and effectiveness of LY4050784 in patients with advanced or metastatic solid tumors that have SMARCA4/BRG1 alterations. This research is significant as it targets patients who have limited treatment options.
In a recent update, Eli Lilly and Company announced the continuation of their Phase 2 study titled ‘An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination With Mirikizumab for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis.’ The study aims to assess the safety and efficacy of eltrekibart and mirikizumab in treating adults with this chronic condition, highlighting its significance in potentially improving treatment options for ulcerative colitis.
Eli Lilly and Company is conducting a Phase 3 study titled ‘Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3).’ The study aims to evaluate the efficacy and safety of retatrutide in managing Type 2 Diabetes in patients with renal impairment who have inadequate glycemic control despite using basal insulin, with or without additional medications.
Study Overview: Eli Lilly and Company is conducting a Phase 1 study titled A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM). The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of LY3938577, particularly its blood sugar-lowering effects compared to Insulin Degludec. This research is significant as it could lead to new treatment options for T1DM.
Study Overview: The REBUILD-1 Study, officially titled A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine, aims to evaluate the efficacy and safety of galcanezumab for preventing episodic migraines in young participants. The primary goal is to establish galcanezumab’s superiority over a placebo in reducing monthly migraine headache days over a three-month period.
Study Overview: Eli Lilly and Company is conducting a global study titled ‘Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease.’ The primary aim is to evaluate the safety and efficacy of donanemab, a promising treatment for early symptomatic Alzheimer’s disease, which could significantly impact patient care and disease management.
Eli Lilly and Company, in collaboration with Rigel Pharmaceuticals, is conducting an adaptive Phase 2a/2b study titled ‘An Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis.’ The study aims to evaluate the efficacy and safety of LY3871801 in treating adults with active moderate-to-severe rheumatoid arthritis, a condition that significantly impacts quality of life.
Study Overview: Eli Lilly and Company is conducting a study titled An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants With Relapsing Multiple Sclerosis. The study aims to evaluate the safety and efficacy of LY3541860 in adults with relapsing multiple sclerosis, a condition characterized by episodes of worsening and improvement. This research is significant as it could lead to new treatment options for managing multiple sclerosis.
Eli Lilly and Company is conducting a master protocol study titled ‘A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain.’ The study aims to evaluate various interventions for chronic pain, including osteoarthritis, diabetic neuropathic pain, and chronic low-back pain. This research is significant as it seeks to establish a comprehensive framework for testing multiple pain interventions.
Eli Lilly and Company is currently conducting a clinical study titled ‘FORAGER-1: A Phase 1, Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer With FGFR3 Alterations’. The study aims to evaluate the safety, side effects, and effectiveness of LOXO-435, either alone or in combination with other cancer treatments, in patients with certain genetic changes in their tumors.
Study Overview: Eli Lilly and Company is conducting a Phase 3, 12-month, open-label study titled ‘PIONEER-PEDS2’ to evaluate the safety and effectiveness of lasmiditan for treating migraines in children aged 6 to 17. This study aims to address the need for effective pediatric migraine treatments, potentially offering a new therapeutic option for this age group.
Study Overview: Eli Lilly and Company is conducting a study titled ‘A Single Dose Study to Evaluate the Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus.’ The study aims to understand how LY3209590, a drug for Type 2 Diabetes Mellitus, is absorbed into the bloodstream and eliminated by the body in children. This research is crucial for developing effective treatments for pediatric diabetes.
Eli Lilly and Company is conducting a Phase 3 study titled ‘A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn’s Disease (SHINE-ON)’. The study aims to evaluate the long-term efficacy and safety of mirikizumab in children and adolescents suffering from moderate-to-severe ulcerative colitis or Crohn’s disease. This research is significant as it addresses the need for effective long-term treatments for these chronic conditions in younger populations.
Eli Lilly and Company, in collaboration with Dermira, Inc., is conducting a Phase 3 clinical study titled ‘A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis.' The study aims to evaluate the effectiveness and safety of lebrikizumab in treating pediatric patients with moderate-to-severe atopic dermatitis, a chronic skin condition also known as eczema.
Eli Lilly and Company is conducting a study titled ‘A Single-Ascending and Repeated Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Who Have the PNPLA3 I148M Genotype.’ The study aims to assess the safety and tolerability of LY3849891 in individuals with MASLD, focusing on those with a specific genetic marker, PNPLA3 I148M.
Study Overview: Eli Lilly and Company is conducting an open-label, randomized study titled Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis. The study aims to assess the safety and effectiveness of baricitinib in treating systemic juvenile idiopathic arthritis (sJIA) in children aged 1 to less than 18 years, a significant step in addressing this challenging condition.
Eli Lilly and Company is currently recruiting for a study titled CAMPFIRE: Children’s and Young Adult Master Protocol for Innovative Pediatric Research (NCT05999994). The study aims to streamline multiple clinical trials for pediatric cancer treatments under a single protocol, enhancing efficiency and adaptability as new drugs are developed.
In a recent update, Eli Lilly and Company announced the continuation of their Phase 3 clinical study on Mirikizumab, aimed at evaluating its efficacy, pharmacokinetics, and safety in pediatric patients aged 2 to less than 18 years with moderately to severely active ulcerative colitis. This study is significant as it seeks to address the unmet medical needs in pediatric ulcerative colitis treatment.
Study Overview: Eli Lilly and Company is conducting a Phase 3 multicenter study titled A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA). The study aims to assess the long-term safety and efficacy of baricitinib in treating juvenile idiopathic arthritis (JIA) in participants aged 1 to 17, highlighting its significance in potentially improving treatment options for this condition.
Study Overview: Eli Lilly and Company is conducting a study titled ‘A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients From 1 Year to Less Than 18 Years Old Hospitalized With COVID-19.’ The study aims to evaluate the safety and effectiveness of baricitinib in treating hospitalized children with COVID-19, which is significant for addressing this vulnerable population’s needs.
Study Overview: Eli Lilly and Company is conducting a clinical trial titled ‘A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults With GRPR-Positive Advanced Solid Tumors (OMNIRAY)’. The study aims to assess the safety, tolerability, and efficacy of LY4257496 in treating GRPR-positive advanced cancers, including breast, colorectal, prostate, and endometrial cancers. This research is significant as it explores a novel treatment approach for these challenging cancer types.
Eli Lilly and Company is conducting a Phase 3 clinical study titled ‘A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn’s Disease (SHINE-ON)’. The study aims to evaluate the long-term efficacy and safety of Mirikizumab in children and adolescents with moderate-to-severe ulcerative colitis or Crohn’s disease. This research is significant as it addresses the need for effective long-term treatments for these chronic conditions in younger populations.
Eli Lilly and Company is conducting a Phase 3 clinical study titled A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis. The study aims to evaluate the effectiveness, safety, and absorption of lebrikizumab in young patients with moderate-to-severe atopic dermatitis, a significant condition affecting many children and adolescents.
Eli Lilly and Company is conducting a clinical study titled A Single-Ascending and Repeated Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Who Have the PNPLA3 I148M Genotype. The study aims to assess the safety and tolerability of LY3849891 in individuals with MASLD, focusing on its effects on liver fibroinflammation and elimination from the body.
In a recent update, Eli Lilly and Company announced ongoing recruitment for their study titled Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis. The study aims to assess the safety and effectiveness of baricitinib in treating systemic juvenile idiopathic arthritis (sJIA) in young patients, highlighting its potential significance in pediatric rheumatology.
Study Overview: Eli Lilly and Company is spearheading the CAMPFIRE study, a master protocol designed to streamline multiple clinical trials targeting pediatric cancers. The study aims to enhance research efficiency by utilizing a unified protocol, allowing for the addition of new trials as novel drugs become available. This approach is significant as it seeks to expedite the development of effective treatments for children and young adults with cancer.
Eli Lilly and Company is conducting a Phase 3 clinical study titled ‘A Multicenter, Phase 3, Open-Label Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age With Moderately to Severely Active Ulcerative Colitis.’ The study aims to evaluate the effectiveness and safety of Mirikizumab in treating pediatric patients with this condition, highlighting its potential significance in addressing unmet medical needs in this demographic.
Study Overview: Eli Lilly and Company is conducting a Phase 3 multicenter study titled ‘A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)'. The study aims to assess the long-term safety and efficacy of the drug Baricitinib in treating Juvenile Idiopathic Arthritis (JIA) in participants aged 1 to 17 years, highlighting its significance in addressing a critical need for effective pediatric arthritis treatments.
Study Overview: Eli Lilly and Company is conducting a study titled A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients From 1 Year to Less Than 18 Years Old Hospitalized With COVID-19. The study aims to evaluate the effectiveness and safety of baricitinib in treating hospitalized children with COVID-19, with a focus on confirming the appropriate dosage.
Study Overview: Eli Lilly and Company is conducting a clinical study titled A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults With GRPR-Positive Advanced Solid Tumors (OMNIRAY). The study aims to assess the safety, tolerability, and efficacy of LY4257496, both alone and in combination with standard care therapies, in patients with GRPR-positive advanced breast, colorectal, prostate, and endometrial cancer. This research is significant as it explores new treatment avenues for these cancer types.
On August 18, 2025, Eli Lilly & Co entered into an underwriting agreement with several financial institutions for the issuance and sale of various notes, including both floating and fixed rate notes, totaling approximately $6.71 billion in net proceeds. This financial maneuver, completed on August 20, 2025, is expected to strengthen the company’s financial position and potentially impact its strategic operations and market presence.
The most recent analyst rating on (LLY) stock is a Hold with a $700.00 price target. To see the full list of analyst forecasts on Eli Lilly & Co stock, see the LLY Stock Forecast page.
Eli Lilly and Company is conducting a groundbreaking study titled A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3954068 in Patients With Early Symptomatic Alzheimer’s Disease. The primary goal is to assess the safety of LY3954068, a new drug aimed at treating early symptomatic Alzheimer’s Disease, and to understand its behavior in the human body.
Eli Lilly and Company is conducting a Phase 1 clinical study titled ‘An Open-Label, Phase 1 Study to Investigate the Comparability of the Pharmacokinetics of Olomorasib (LY3537982) Between Two Capsule Formulations and to Evaluate the Food Effect in Healthy Japanese Participants.’ The study aims to compare how food affects the absorption of Olomorasib in two different capsule forms, highlighting its significance in optimizing drug delivery.
Eli Lilly and Company recently completed a Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Japanese Adult Participants With Obesity Disease.’ The study aimed to evaluate the effectiveness and safety of orforglipron, a new oral medication, in treating obesity-related health issues.
Study Overview: Eli Lilly and Company is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1).’ The study aims to evaluate the effectiveness and safety of Orforglipron, a potential treatment for obesity and related conditions, highlighting its significance in addressing a growing global health concern.
The recent update from Eli Lilly and Company and Prevail Therapeutics involves a Phase 1/2a clinical trial titled ‘A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson’s Disease With at Least One GBA1 Mutation (PROPEL)’. The study aims to assess the safety and effects of LY3884961 in patients with moderate to severe Parkinson’s disease who have at least one pathogenic GBA1 mutation. This study is significant as it explores a potential new treatment avenue for a specific subset of Parkinson’s patients.
Pfizer, in collaboration with Eli Lilly and Company, ONO Pharmaceutical Co., and Merck KGaA, is conducting a Phase 3 clinical study titled ‘AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER.’ The study aims to evaluate the efficacy of encorafenib plus cetuximab, with or without chemotherapy, compared to standard chemotherapy in patients with metastatic colorectal cancer with the BRAF V600E mutation. This study is significant as it explores new treatment combinations for a cancer type that has spread and has not been previously treated.
Eli Lilly and Company, in collaboration with Pfizer Inc and other industry leaders, is conducting a Phase 2 clinical study titled A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer. The study aims to evaluate the effectiveness of combining encorafenib and cetuximab with pembrolizumab versus using pembrolizumab alone in treating metastatic colorectal cancer with specific genetic mutations. This research is significant as it explores new treatment avenues for patients with limited options.
Eli Lilly and Company is conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1).’ The study aims to evaluate the effectiveness and safety of Orforglipron, an oral medication, in adults with obesity or overweight conditions accompanied by related health issues.
Study Overview: Eli Lilly and Company recently completed a Phase 3 study titled A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Japanese Adult Participants With Obesity Disease. The study aimed to evaluate the effectiveness and safety of orforglipron, an oral medication, in treating obesity-related health issues among Japanese adults.
Eli Lilly’s recent earnings call painted a picture of robust growth tempered by some challenges. The company reported strong revenue growth, successful clinical trials, and strategic acquisitions, though these positives were offset by pricing and market access challenges, as well as geographical headwinds. Despite these hurdles, Eli Lilly remains committed to addressing these issues and maintaining its growth trajectory.
Eli Lilly and Company is conducting a study titled A Multiple Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis. The study aims to evaluate the safety and side effects of LY4256984 in individuals with sporadic ALS, a progressive neurodegenerative disease.
Eli Lilly and Company is conducting a Phase 1a/1b clinical study titled A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors. The study aims to evaluate the safety and tolerability of the investigational drug LY4066434 in patients with locally advanced or metastatic solid tumors with specific KRAS mutations. This research is significant as it explores new treatment avenues for these challenging cancer types.
The recent clinical study titled ‘A Phase 1/2 Trial of AAVAnc80-antiVEGF Gene Therapy in Individuals With Unilateral Vestibular Schwannoma’ aims to assess the safety and tolerability of a novel gene therapy. Sponsored by Akouos, Inc., in collaboration with Eli Lilly and Company, this study focuses on a single unilateral administration of AAVAnc80-antiVEGF to treat vestibular schwannoma, a condition affecting the balance and hearing nerves.
The recent clinical study update from Eli Lilly and Company, in collaboration with ALX Oncology Inc., focuses on a Phase 2/3 trial titled ‘A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)’. The study aims to evaluate the efficacy of Evorpacept in combination with other drugs for patients with advanced HER2+ gastric cancer, highlighting its potential significance in improving treatment outcomes for this challenging condition.
Study Overview: Eli Lilly and Company is conducting a Phase 1 study titled A Phase 1, Open-Label, Single and Multiple Dose Study to Investigate the Safety, Tolerability, and Relative Bioavailability of Single and Multiple Weekly Subcutaneous Doses of Eloralintide, and Single and Multiple Weekly Subcutaneous Doses of Eloralintide With Tirzepatide in Participants With Overweight or Obesity. The study aims to evaluate the safety and tolerability of eloralintide alone and in combination with tirzepatide in overweight or obese individuals, focusing on how these drugs are absorbed and processed by the body.
Study Overview: Eli Lilly and Company is launching a Phase 1 clinical study titled A Multiple Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis. The study aims to evaluate the safety and tolerability of LY4256984 in individuals with sporadic ALS, a progressive neurodegenerative disease, highlighting its potential significance in addressing unmet medical needs.
Study Overview: Eli Lilly and Company is conducting a study titled A Multiple Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis. The study aims to evaluate the safety and tolerability of LY4256984 in patients with sporadic ALS, a significant step in understanding the treatment’s potential impact on this debilitating condition.
Eli Lilly And Company, AbbVie, and Genmab are collaborating on a clinical study titled A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter’s Syndrome. The study aims to evaluate the safety and efficacy of epcoritamab, a promising antibody treatment, in patients with challenging forms of leukemia and lymphoma, offering potential new therapies for these conditions.
Eli Lilly and Company is conducting a clinical study titled A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 3 Trial to Investigate the Efficacy and Safety of Lebrikizumab When Used With/Without Topical Corticosteroid Treatment in Participants With Moderate-To-Severe Atopic Dermatitis. The study aims to evaluate the effectiveness and safety of lebrikizumab, with or without topical corticosteroids, in treating moderate-to-severe atopic dermatitis over approximately 62 weeks.
Eli Lilly and Company has announced a new clinical study titled A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4088044 in Healthy Participants. The study aims to assess the safety and tolerability of LY4088044, a drug administered either subcutaneously or intravenously, in healthy individuals. This study is significant as it explores the pharmacokinetics and pharmacodynamics of LY4088044, providing crucial data for future drug development.